J&J jumps in on Actelion spinout's hypertension drug

Through a collaboration deal, Idorsia is handing over rights to aprocitentan in exchange for a $230 million milestone payment.

By Jacob Bell • Dec. 4, 2017

The BioPharma Dive Awards for 2017

The 2017 BioPharma Dive Awards recognize the industry’s top innovators and disruptors. These executives, companies and trends are transforming the industry and shaping what's to come.

By Ned Pagliarulo , Lisa LaMotta , Jacob Bell • Dec. 4, 2017

Deal of the Year: Gilead Buys Kite Pharma

Faced with a waning hepatitis C business, Gilead finally came off the M&A sidelines to buy itself a leading position in CAR-T cell therapy. 

By Ned Pagliarulo • Dec. 4, 2017

Astellas picks up Mitobridge for rare mitochondrial diseases

By exercising its option, Astellas has snagged access to a clinical stage mitochondrial disease therapeutic.

By Suzanne Elvidge • Dec. 4, 2017

CVS Health to buy Aetna in $69B deal

The deal would combine CVS's retail pharmacy services with Aetna's health insurance business, creating a healthcare giant with significant market power.

By Jeff Byers , Shannon Muchmore • Dec. 3, 2017

Prescribed Reading: Industry CEOs talk PRVs, IPR, PCSK9

Leschly suggests PRVs should be an alternative source of revenue for biotechs; ear health R&D is all clogged up; and execs agree the IPR process should be thrown out. 

By Lisa LaMotta • Dec. 1, 2017

Medicines Co. sells infectious disease unit to put more money into PCSK9 drug

Pure-play antibiotics developer Melinta has agreed to acquire the unit for $270 million in guaranteed cash and equity.

By Jacob Bell • Nov. 29, 2017

AstraZeneca outlicenses Brilinta reversal agent

Though still preclinical, PB2452 could bolster the safety profile of AstraZeneca's blood thinner if it reaches the market.

By Jacob Bell • Nov. 28, 2017

How Anthem's new PBM will impact pharma

David Henka, CEO of RxTE Health, sat down with BioPharma Dive to discuss the implications of a new pharmacy benefit manager entering the marketplace. 

By Jacob Bell • Nov. 28, 2017

Biogen, Alkermes hook up on Tecfidera follow-on

Biogen is looking to limit competition to its blockbuster multiple sclerosis drug by buying into a follow-on version being developed by Alkermes. 

By Suzanne Elvidge • Nov. 28, 2017

BioMarin sells latest PRV for $125M

The biotech monetized its coveted priority review voucher, boosting its finances.

By Lisa LaMotta • Nov. 27, 2017

AMR Centre launches, announces new antimicrobial agreement

The launch of the AMR Centre at Alderley Park in the UK aims to fill the gap between basic research and the market for new antimicrobials.

By Suzanne Elvidge • Nov. 22, 2017

Prescribed Reading: FDA on approval streak, I/O shines

The regulatory agency granted seven approvals this week, including the first pill with a digital sensor, as well as the go-ahead for a new hemophilia drug. 

By Lisa LaMotta • Nov. 17, 2017

Merck strikes autoimmune deal with newly emerged Cue

The deal is right on cue, as the startup only emerged from stealth mode in January.

By Suzanne Elvidge • Nov. 17, 2017

Purdue pivots to oncology amidst opioid crisis

Better known for its prescription painkillers, the company has added four cancer drugs to its arsenal as backlash from the U.S. opioid epidemic intensifies.

By Suzanne Elvidge • Nov. 15, 2017

Loxo parlays cancer drug success into $1.5B deal with Bayer

The German drugmaker will pay $400 million upfront for partial rights to Loxo's rare cancer drug, lured by the promise of precision medicine.

By Ned Pagliarulo • Nov. 14, 2017

Zymeworks adds 6th pharma partner with J&J deal

The large pharma will pay $50 million upfront to gain access to Zymeworks' bispecific antibody platforms.

By Ned Pagliarulo • Nov. 13, 2017

Dynacure secures rights to Ionis rare disease drug

A collaboration between the companies takes a step forward, with the French biotech licensing one of Ionis' early-stage antisense candidates.

By Suzanne Elvidge • Nov. 10, 2017

Prescribed Reading: Buyer's remorse for biopharma

Most of the major deal developments of late have been companies handing back the rights to assets they previously licensed as they try to right-size portfolios. 

By Lisa LaMotta • Nov. 10, 2017

Sanofi picks up BTK inhibitor for MS development

After ending its fruitful deal with Regeneron, Sanofi acquires a new asset to add to its roster of potential blockbusters. 

By Lisa LaMotta • Nov. 9, 2017

Takeda pursuing needle-free delivery for its top-selling biologic

Linking up with Portal Instruments, the pharma is developing a device that uses pressurized liquid to administer biologics and plans to test it first with Entyvio.

By Jacob Bell • Nov. 8, 2017

Dermira drops UCB drug to fund other launches

Returning Cimzia rights gets Dermira $11 million in 2017 and $39 million in 2018 that could help fund its late-stage portfolio. 

By Suzanne Elvidge • Nov. 7, 2017

Valeant hands Sprout back to former owners

Despite paying $1 billion to buy the company two years ago, Valeant never found success in selling Sprout's female libido drug Addyi.

By Jacob Bell • Nov. 6, 2017

Mallinckrodt continues pipeline revamp with Ocera buy

The deal gives Mallinckrodt access to hepatic encephalopathy drug OCR-002, which the company believes can make a turn around in the clinic.

By Jacob Bell • Nov. 3, 2017

Prescribed Reading: Cancer market facing several shake-ups

Merck pulled a Keytruda application in Europe, and AstraZeneca got a key approval for Calquence — decisions that could have dramatic impacts on different areas of the oncology space. 

By Lisa LaMotta • Nov. 3, 2017